论文部分内容阅读
目的观察和评价吉西他滨作为二线化疗方案治疗早期复发小细胞肺癌的疗效。方法回顾性分析2005年12月至2010年12月我科经病理证实的早期复发小细胞肺癌38例。吉西他滨(泽菲)给药剂量按1.0g/m2,d1、8d,静滴1h,每3周重复,每例至少接受2周期化疗后评价疗效。结果全组38例均可评价疗效,有效率(CR+PR)28.95%(11/38),SD 18.42%(7/38),PD 52.63%(20/38),中位疾病进展时间14周,中位生存期26周。治疗相关毒副反应主要为血小板减少,Ⅲ-Ⅳ级血小板减少为5.26%(2/38)。结论吉西他滨可以作为早期复发小细胞肺癌的二线化疗方案。
Objective To observe and evaluate the efficacy of gemcitabine as a second-line chemotherapy for early-stage recurrent small cell lung cancer. Methods Retrospective analysis of 38 cases of early-stage recurrent small cell lung cancer confirmed by pathology from December 2005 to December 2010 in our department. Gemcitabine (Saffi Fei) dose of 1.0g / m2, d1, 8d, intravenous infusion 1h, repeated every 3 weeks, each case received at least two cycles of chemotherapy after the evaluation of efficacy. Results All the 38 patients were evaluated with CR (PR) 28.95% (11/38), SD 18.42% (7/38), PD 52.63% (20/38), median disease progression time 14 weeks , Median survival of 26 weeks. Toxic side effects of treatment were mainly thrombocytopenia, grade III-IV thrombocytopenia was 5.26% (2/38). Conclusion Gemcitabine can be used as a second-line chemotherapy for early-stage small cell lung cancer.